100 related articles for article (PubMed ID: 17050789)
1. Pharmacokinetics of nelfinavir in subjects with hepatic impairment.
Damle B; Hewlett D; Hsyu PH; Becker M; Petersen A
J Clin Pharmacol; 2006 Nov; 46(11):1241-9. PubMed ID: 17050789
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.
Bergshoeff AS; Fraaij PL; van Rossum AM; Wolfs TF; Geelen SP; de Groot R; Burger DM
Antivir Ther; 2003 Jun; 8(3):215-22. PubMed ID: 12924538
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum.
van Heeswijk RP; Khaliq Y; Gallicano KD; Bourbeau M; Seguin I; Phillips EJ; Cameron DW
Clin Pharmacol Ther; 2004 Dec; 76(6):588-97. PubMed ID: 15592330
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
Crommentuyn KM; Scherpbier HJ; Kuijpers TW; Mathôt RA; Huitema AD; Beijnen JH
Pediatr Infect Dis J; 2006 Jun; 25(6):538-43. PubMed ID: 16732153
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects.
Regazzi M; Maserati R; Villani P; Cusato M; Zucchi P; Briganti E; Roda R; Sacchelli L; Gatti F; Delle Foglie P; Nardini G; Fabris P; Mori F; Castelli P; Testa L
Antimicrob Agents Chemother; 2005 Feb; 49(2):643-9. PubMed ID: 15673746
[TBL] [Abstract][Full Text] [Related]
6. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects.
Fang AF; Damle BD; LaBadie RR; Crownover PH; Hewlett D; Glue PW
Pharmacotherapy; 2008 Jan; 28(1):42-50. PubMed ID: 18154473
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
[TBL] [Abstract][Full Text] [Related]
8. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.
Hirt D; Treluyer JM; Jullien V; Firtion G; Chappuy H; Rey E; Pons G; Mandelbrot L; Urien S
Antimicrob Agents Chemother; 2006 Jun; 50(6):2079-86. PubMed ID: 16723569
[TBL] [Abstract][Full Text] [Related]
9. A study of the pharmacokinetics of azithromycin and nelfinavir when coadministered in healthy volunteers.
Amsden GW; Nafziger AN; Foulds G; Cabelus LJ
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1522-7. PubMed ID: 11185676
[TBL] [Abstract][Full Text] [Related]
10. Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate.
Boffito M; Pozniak A; Kearney BP; Higgs C; Mathias A; Zhong L; Shah J
Antimicrob Agents Chemother; 2005 Oct; 49(10):4386-9. PubMed ID: 16189129
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment.
Marbury T; Dowell JA; Seltzer E; Buckwalter M
J Clin Pharmacol; 2009 Apr; 49(4):465-76. PubMed ID: 19318696
[TBL] [Abstract][Full Text] [Related]
12. Single dose pharmacokinetics of manidipine in hepatic impaired patients and healthy controls.
Deroubaix X; Lins RL; Lens S; Allemon A; Jeanbaptiste B; Poli G; Acerbi D; Stockis A; Ventura P
Int J Clin Pharmacol Ther; 1998 Jul; 36(7):386-91. PubMed ID: 9707354
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers.
Aarnoutse RE; Droste JA; van Oosterhout JJ; Koopmans PP; Popescu M; Reiss P; Hekster YA; Burger DM
Br J Clin Pharmacol; 2003 Feb; 55(2):115-25. PubMed ID: 12580982
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment.
Butler K; Teng R
J Clin Pharmacol; 2011 Jul; 51(7):978-87. PubMed ID: 20926753
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
Periclou A; Ventura D; Rao N; Abramowitz W
Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
[TBL] [Abstract][Full Text] [Related]
16. Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets.
Abdallah H; Jerling M
J Clin Pharmacol; 2005 Jul; 45(7):802-9. PubMed ID: 15951470
[TBL] [Abstract][Full Text] [Related]
17. The effect of hepatic insufficiency on the safety and pharmacokinetics of paricalcitol (Zemplar).
Carr RA; André AK; Chen P; Grabowski BA; Chang MS; Locke CS; Williams LA; Chojkier M
Nephron Clin Pract; 2006; 103(3):c100-5. PubMed ID: 16534233
[TBL] [Abstract][Full Text] [Related]
18. The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers.
Sarapa N; Hsyu PH; Lappin G; Garner RC
J Clin Pharmacol; 2005 Oct; 45(10):1198-205. PubMed ID: 16172185
[TBL] [Abstract][Full Text] [Related]
19. Effects of obesity induced by high-fat diet on the pharmacokinetics of nelfinavir, a HIV protease inhibitor, in laboratory rats.
Sugioka N; Haraya K; Fukushima K; Ito Y; Takada K
Biopharm Drug Dispos; 2009 Dec; 30(9):532-41. PubMed ID: 19862765
[TBL] [Abstract][Full Text] [Related]
20. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.
Migoya EM; Stevens CH; Bergman AJ; Luo WL; Lasseter KC; Dilzer SC; Davies MJ; Wagner JA; Herman GA
Can J Clin Pharmacol; 2009; 16(1):e165-70. PubMed ID: 19221403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]